Problem

Empirical Health targets the expensive, reactive way healthcare handles chronic illness: the company says the U.S. spends $1.1 trillion annually reacting to complications while investing only a fraction as much in prevention. It also points to evidence that strong primary-care models can reduce hospitalizations by 51% and total care costs by 15–30%, but notes that conventional models are labor-intensive and difficult to scale.

The clearest current use case is preventing heart disease, the world’s leading killer, even though Empirical cites that 80% of heart disease is preventable. The underlying pain is that people may have meaningful cardiovascular risk in their lab results and wearable data but lack an affordable, convenient way to translate those signals into a specific medical, nutrition, and exercise plan.

Product / Service

Empirical combines an at-home digital experience with local laboratory testing and virtual medical care. Its heart-health program starts with one lab visit measuring more than 100 cardiovascular, metabolic, nutritional, and inflammatory biomarkers, including ApoB and Lp(a), at more than 2,000 testing locations. The app then provides heart-risk scores, longitudinal tracking, wearable integrations, nutrition tracking, and personalized recommendations; the standard panel is advertised at $190 with no hidden costs.

The service is designed to turn raw biomarker, symptom, medical-record, and wearable data into actionable care. Empirical’s AI-enabled clinical software helps physicians interpret that information, while a doctor can create individualized treatment, nutrition, and exercise plans and provide medical care such as diagnosis, prescriptions, lab orders, imaging, and referrals. Empirical describes its care operation as a licensed virtual medical practice, while its terms say the company provides administrative and management services to independent physician-owned practices.

Market

Empirical sits at the intersection of AI-native virtual primary care, preventive heart-health services, and consumer biomarker or “functional health” testing. Its named comparison set includes Function Health, Superpower, and InsideTracker; Function is a particularly direct benchmark because both companies offer broad blood panels, while Empirical differentiates on lower pricing, wearable integrations, nutrition and exercise programs, risk scoring, and follow-up medical care.

The public evidence shows an active early-stage company rather than a clearly pre-revenue venture. Y Combinator identifies Empirical as a Summer 2023 company and reports that it is licensed to deliver care in more than 30 states covering over 200 million people, with growth above 25% monthly. The same profile does not provide a customer count or verified revenue figure, so the strongest defensible traction signals are geographic availability, reported growth, the live paid $190 product, and expansion from its initial state-by-state launch into a nationwide offering.